Relative sensitivity and specificity estimates, 95% CI and p values for difference in matched proportions
| Comparison | Outcome | Relative sensitivity (95% CI) | p McNemar | Relative specificity (95% CI) | p McNemar |
|---|---|---|---|---|---|
| Vaginal vs cervical hrHPV | CIN2+ | 0.97 (0.94 to 1.00) | 0.1250 | 0.98 (0.97 to 0.99)* | <0.0001 |
| Urine vs cervical hrHPV | CIN2+ | 0.67 (0.59 to 0.76) | <0.0001 | 1.05 (1.04 to 1.06) | <0.0001 |
| Cytology vs cervical hrHPV | CIN2+ | 0.78 (0.71 to 0.87) | <0.0001 | 1.11 (1.09 to 1.12) | <0.0001 |
| Vaginal vs cervical hrHPV | CIN3+ | 0.97 (0.93 to 1.01) | 0.5000 | 0.98 (0.97 to 0.99)* | <0.0001 |
| Urine vs cervical hrHPV | CIN3+ | 0.53 (0.42 to 0.67) | <0.0001 | 1.03 (1.02 to 1.04) | <0.0001 |
| Cytology vs cervical hrHPV | CIN3+ | 0.77 (0.68 to 0.88) | <0.0001 | 1.11 (1.09 to 1.12) | <0.0001 |
*Fulfils guidelines for HPV test validation in cervical cancer screening3 (relative sensitivity >0.90; relative specificity >0.98).
hrHPV, high-risk human papillomavirus.